With the use of increased dosages of gefitinib, CSF concentrations of gefitinib were over 40 nM, exceeding the in vitro IC50 in H3255 and DFCILU-011, two NSCLC cell lines with sensitizing mutations in the EGFR [18, 19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.